In the current myeloma landscape, do you make treatment decisions based on MRD results, either for MRD negativity or MRD resurgence?

Not yet

For >90% of my patients with myeloma, I agree with @Dr. First Last's succinct answer below. I discuss the MASTER trial with them, but many who were considering stopping treatment (e.g., len maintenance) anyways were already considering doing so based on other toxicities such as fatigue, financial toxicity, fear about side effects, and so forth. So MRD negativity helps to reassure us about stopping treatment.

The only time where I do check MRD more consistently is following CAR-T and bispecific an...